トランスフェクション技術市場：現状分析および予測（2022年～2028年）

トランスフェクション技術の市場規模は、予測期間中に約8%のCAGRで拡大すると予測されています。トランスフェクションは、宿主細胞の遺伝的内容を変更できるため、正常な細胞プロセス、疾患の分子メカニズム、遺伝子治療効果の研究などに幅広く応用されています。トランスフェクションは、遺伝子または遺伝子産物の機能と制御の研究、トランスジェニック生物の生産、および遺伝子治療の方法として、強力な分析ツールとなっています。

当レポートは、世界のトランスフェクション技術市場について調査し、市場の概要とともに、タイプ別、用途別、技術別、エンドユーザー別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場のイントロダクション

第2章 調査方法または仮定、市場の定義

第3章 市場要約

第4章 エグゼクティブサマリー

第5章 COVID-19がトランスフェクション技術市場に与える影響

第6章 トランスフェクションテクノロジー市場の収益（10億米ドル）、2020年～2028年

第7章 製品タイプ別の市場洞察

• 試薬
• 装置
• その他

第8章 用途別の市場洞察

• 治療薬投与
• 生物医学研究
• タンパク質産生
• その他

第9章 技術別の市場洞察

• 物理的トランスフェクション
• 生化学ベースのトランスフェクション
• ウイルスベクターベースのトランスフェクション

第10章 エンドユーザー別の市場洞察

• 研究センター・学術機関
• 病院・診療所
• 製薬会社・バイオテクノロジー企業
• その他

第11章 地域別の市場洞察

• 北米
• 欧州
• アジア太平洋
• その他の地域

第12章 トランスフェクション技術市場力学

• 市場促進要因
• 市場の課題
• 影響分析

第13章 トランスフェクション技術の市場機会

第14章 トランスフェクション技術の市場動向

第15章 需要側と供給側の分析

第16章 バリューチェーン分析

第17章 競合シナリオ

第18章 会社概要

• Lonza Group Ltd.
• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories Inc.
• Roche
• QIAGEN
• Mirus Bio LLC
• SignaGen Laboratories
• Genlantis Inc.
• OZ Biosciences
• Promega Corporation

第19章 免責事項

The transfection technologies market is expected to witness a CAGR of around 8% during the forecast period. Transfection is a modern and powerful method used to insert foreign nucleic acids into eukaryotic cells. The ability to modify host cells' genetic content enables the broad application of this process in studying normal cellular processes, disease molecular mechanisms, and gene therapeutic effects. Biosimilar drug development is accelerated as several drug patents are anticipated to lapse in the coming years. A combination of cytological, genomic, and proteomic analysis is crucial to their development. As a result, the use of transfection equipment and reagents in proteomic and genomic research has grown. Furthermore, rising cases of cancer & high demand for synthetic genes will increase the growth of the transfection technologies market. For instance, according to the data provided by the International Agency for Research on Cancer (IRAC) in 2018, it is estimated that there will be more than 27.5 million new cancer cases by 2040. Also, the two main purposes of transfection are to produce recombinant proteins or to specifically enhance or inhibit gene expression in transfected cells. As such, transfection is a powerful analytical tool for the study of the function and regulation of genes or gene products, for the production of transgenic organisms, and as a method for gene therapy.

Based on product type, the market is segmented into reagents, instruments, and others. Among them, the reagent category is to witness lucrative growth during the forecast period. This growth can be attributed to factors like advancements in transfection technology, global alliances between leading research institutes to spur drug discovery, rising pharmaceutical and biotechnology companies' R&D spending and research activities, an increase in demand for synthetic genes, and a rise in the prevalence of cancer.

On the basis of application, the market is categorized into therapeutic delivery, bio-medical research, protein production, and others. Among these, the therapeutic delivery category is anticipated to register a lucrative CAGR during the forecast period. This is mainly due to the rising demand for precise therapeutic procedures and intensifying research and development activities associated with novel drug and transfection technique discoveries.

Based on technology, the transfection technologies market has been classified into physical transfection, biochemical-based transfection, and viral-vector-based transfection. The viral-vector-based transfection category to hold a significant share in the market during the forecast period. This is mainly due to the growing prominence of gene and cell therapy products and increasing funding activities are the key driving factors fueling the growth of the market.

Based on end-user, the transfection technologies market has been classified into research centers and academic institutes, hospitals and clinics, pharmaceutical and biotechnology companies, and others. The pharmaceutical and biotechnology companies category is to witness higher adoption of transfection technologies during the forecast period. This is mainly due to the growing biopharmaceuticals and technological advancements that will drive the growth of the global transfection technologies market. Besides, the rising government funding to leading research institutes in developed countries for drug development will also drive the transfection technologies market.

For a better understanding of the market adoption of the transfection technologies market, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to grow at a substantial CAGR during the forecast period. This is mainly due to the presence of cutting-edge research labs and leading pharmaceutical companies that are continuously contributing to research and development. The full-fledged economies of the states in North America force them to spend an incalculable amount of money on developing modern treatments. Additionally, the rising obesity and breast cancer rates in the US are the major contributor to this sector's dominance in the transfection technologies market. For instance, in 2020, there were 2.3 million women diagnosed with breast cancer and 685 000 deaths globally. As of the end of 2020, there were 7.8 million women who were diagnosed with breast cancer in the past 5 years, making it the world's most prevalent cancer.

Some of the major players operating in the market include: Lonza Group Ltd., Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Roche, QIAGEN, Mirus Bio LLC, SignaGen Laboratories, Genlantis Inc., OZ Biosciences, and Promega Corporation.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Transfection Technologies Market
• 2.2. Research Methodology of the Transfection Technologies Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE TRANSFECTION TECHNOLOGIES MARKET

6 TRANSFECTION TECHNOLOGIES MARKET REVENUE (USD BN), 2020-2028F

7 MARKET INSIGHTS BY PRODUCT TYPE

• 7.1. Reagent
• 7.2. Instrument
• 7.3. Others

8 MARKET INSIGHTS BY APPLICATION

• 8.1. Therapeutic Delivery
• 8.2. Bio-Medical Research
• 8.3. Protein Production
• 8.4. Others

9 MARKET INSIGHTS BY TECHNOLOGY

• 9.1. Physical Transfection
• 9.2. Biochemical-Based Transfection
• 9.3. Viral-Vector-Based Transfection

10 MARKET INSIGHTS BY END-USER

• 10.1. Research Centers and Academic Institutes
• 10.2. Hospitals and Clinics
• 10.3. Pharmaceutical and Biotechnology Companies
• 10.4. Others

11 MARKET INSIGHTS BY REGION

• 11.1. North America
  • 11.1.1. U.S.
  • 11.1.2. Canada
  • 11.1.3. Rest of North America
• 11.2. Europe
  • 11.2.1. Germany
  • 11.2.2. U.K.
  • 11.2.3. France
  • 11.2.4. Italy
  • 11.2.5. Spain
  • 11.2.6. Rest of Europe
• 11.3. Asia-Pacific
  • 11.3.1. China
  • 11.3.2. Japan
  • 11.3.3. India
  • 11.3.4. Rest of Asia-Pacific
• 11.4. Rest of World

12 TRANSFECTION TECHNOLOGIES MARKET DYNAMICS

• 12.1. Market Drivers
• 12.2. Market Challenges
• 12.3. Impact Analysis

13 TRANSFECTION TECHNOLOGIES MARKET OPPORTUNITIES

14 TRANSFECTION TECHNOLOGIES MARKET TRENDS

15 DEMAND AND SUPPLY-SIDE ANALYSIS

• 15.1. Demand Side Analysis
• 15.2. Supply Side Analysis

16 VALUE CHAIN ANALYSIS

17 COMPETITIVE SCENARIO

• 17.1. Competitive Landscape
  • 17.1.1. Porters Five Forces Analysis

18 COMPANY PROFILED

• 18.1. Lonza Group Ltd.
• 18.2. Thermo Fisher Scientific Inc.
• 18.3. Bio-Rad Laboratories Inc.
• 18.4. Roche
• 18.5. QIAGEN
• 18.6. Mirus Bio LLC
• 18.7. SignaGen Laboratories
• 18.8. Genlantis Inc.
• 18.9. OZ Biosciences
• 18.10. Promega Corporation

19 DISCLAIMER